The move broadens treatment choices for pediatric patients aged 10 years and older whose diabetes remains uncontrolled with ...

Dr Suchitra Sundaram shares key highlights on frontline time limited and all oral regimens producing deep MRD responses, ...

Phase 3 studies point to sustained disease control in patients who remain symptomatic despite standard therapies.

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting ...

The decision applies to adolescents and adults and aligns with earlier US authorization for higher-risk groups.

The recommendation addresses a long-standing treatment gap for patients facing bladder removal after standard therapy fails.

Despite reported slowing of progression, regulators said the evidence on the novel oral agent blarcamesine did not support a ...

The patchwork rollout of a gene therapy exposes weaknesses in the pricing and regulatory frameworks that determine who ...

Adjunctive treatment with the GLP-1 agonist semaglutide significantly reduces the antipsychotic-related cardiometabolic risk ...

A 2025 report cowritten by Iyengar that quoted federal data, said that the 5-year DLBCL survival is approximately 80% in ...

In a Medscape survey, doctors became slightly more enthusiastic about the future of artificial intelligence (AI) in their ...

Soybean oil is regarded as beneficial to health, but this study suggests that you can have too much of a good thing and ...